Nokia has proclaimed a private 5G trial at a production plant at the Institute of Immunobiological Technology (Bio-Manguinhos) in Rio de Janeiro in Brazil as a connectivity springboard to enhance vaccine manufacturing. Bio-Manguinhos produces active pharmaceutical ingredients (APIs; not those ones) for vaccines for mumps and measles, among other things. The new solution “could prevent […]

The post Nokia hails ‘unprecedented’ private 5G trial at vaccine plant in Brazil appeared first on RCR Wireless News.